HeartBeat.bio has secured €4.5 million in a Pre-Series A financing initiative. The Vienna-based biotech innovator specializes in human organoid systems and AI to advance heart disease treatment.

With backing from leaders like i&i Biotech Fund and Invest AG, including aws Gründungsfonds II and Tensor Ventures, the infusion is targeted at perfecting cardioid drug discovery.